Autosomal Dominant Optic Atrophy (ADOA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Autosomal Dominant Optic Atrophy (ADOA) Market Outlook
Thelansis’s “Autosomal Dominant Optic
Atrophy (ADOA) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Autosomal Dominant Optic Atrophy
(ADOA) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Autosomal
Dominant Optic Atrophy (ADOA) Overview
Autosomal
dominant optic atrophy (ADOA) is a rare hereditary disorder characterized by
progressive and irreversible vision loss in both eyes, typically commencing in
the first decade of life. Around 80% of affected individuals manifest symptoms
before the age of 10, with onset frequently occurring between the ages of 4 and
6. Hallmark clinical features of ADOA include central visual field defects and
impaired color vision. The disease exhibits significant phenotypic variability
among family members, making it challenging to predict the decline and
progression of visual acuity. Many affected children eventually progress to
blindness. About 50% of individuals with ADOA do not meet driving standards,
and up to 46% are classified as legally blind. A subset of approximately 20% of
patients presents with a more severe phenotype known as ADOA “plus” syndrome,
which encompasses additional non-ocular manifestations such as permanent
hearing loss and other severe conditions impacting the nervous system and
skeletal muscles.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment